Critics pounce on Gottlieb's pharma ties as FDA commissioner hearings begin

Fierce Pharma -------- The day before Scott Gottlieb faced a Senate committee on Wednesday, the FDA commissioner nominee hit pushback from Democrats who say he’s too entangled in the pharma industry to be an independent regulator. And that line of questioning continued on Wednesday as his confirmation got underway on Capitol Hill. At the same time, the pharma industry continues to hail President Donald Trump’s FDA pick as a pragmatic leader who understands both drug development and regulation—and much less dangerous to biopharma than the more unconventional candidates Trump had floated. On Wednesday, some members of Senate hailed his experience, with Sen. Richard Burr, R-N.C., saying the "criticisms are about his successes." To learn more click on the picture below to read the article.